Relatively new to Starpharma - bought in around mid 2020 on the basis of DEP potential. I really don't understand why management keep promoting Viralese. With all the approvals granted in UK, India, Vietnam etc it appears not very beneficial financially. Since 2016 revenue, operating income and margins, net income, share dilution and return on equity are all worse Unless I am missing something why bother with Viralese?
SPL Price at posting:
$1.04 Sentiment: Hold Disclosure: Held
